Afuco™ Anti-TGFB2 ADCC Recombinant Antibody (Lerdelimumab), ADCC Enhanced (CAT#: AFC-TAB-100)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to TGF beta 2. Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Subcellular Location
RNA Expression

Specifications

  • Immunogen
  • An epitope of TGF beta 2 (Human).
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Clone
  • Lerdelimumab
  • Applications
  • ELISA, IP, FC, FuncS, Neut, IF
  • Conjugate
  • Unconjugated
  • Trade name
  • Trabio
  • Generic Name
  • Lerdelimumab
  • Related Disease
  • Glaucoma surgery

Product Property

  • Purity
  • >95% by SDS-PAGE
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • Lerdelimumab; Trabio; CAT-152; 6B1; Anti-TGF-Beta-2; Trabio; Trabio; CAT-152; TGFB2; transforming growth factor, beta 2; transforming growth factor beta-2; G-TSF; cetermin; polyergin; BSC-1 cell growth inhibitor; glioblastoma-derived T-cell suppressor factor; TGF-beta2

Related Resources

  • Biosimilar Overview
  • Related Diseases
Please refer to Lerdelimumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Lerdelimumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Lerdelimumab"

Anti-Human TGF beta 2 Recombinant Antibody (Lerdelimumab)
Recombinant monoclonal antibody to TGF beta 2. Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery.

See other products for "TGFB2"

Select a product category from the dropdown menu below to view related products.
Please select product type
Recombinant Antibody Fab Fragment Antibody scFv Fragment Antibody Human Antibody Neutralizing Antibody

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for AFC-TAB-100. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare